Journal Mobile Options
Table of Contents
Vol. 131, No. 1, 2003
Issue release date: May 2003
Section title: Original Paper
Int Arch Allergy Immunol 2003;131:25–32
(DOI:10.1159/000070431)

Inflammatory Role of Two Venom Components of Yellow Jackets (Vespula vulgaris): A Mast Cell Degranulating Peptide Mastoparan and Phospholipase A1

King T.P. · Jim S.Y. · Wittkowski K.M.
The Rockefeller University, New York, N.Y., USA

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 9/17/2002
Accepted: 12/19/2002
Published online: 5/16/2003
Issue release date: May 2003

Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 2

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: http://www.karger.com/IAA

Abstract

Background: Venom sac extract of yellow jackets Vespula vulgaris was toxic in mice when injected intraperitoneally but not toxic when injected subcutaneously. Necropsy showed the toxicity to be an inflammatory response. Methods: Venom peptide and protein fractions were tested to identify the inflammatory components. The active components were tested to establish whether they might function as adjuvant for venom protein-specific antibody response. Results: Venom toxicity required the synergistic action of two venom components, a mast cell degranulating peptide mastoparan and phospholipase A1. Both components stimulated prostaglandin E2 release from murine peritoneal cells and macrophages. Mastoparan showed a weak activity to enhance IgE and IgG1 responses to a yellow jacket venom protein Ves v 5 in BALB/c mice. It was not possible to assess the adjuvant activity of phospholipase A1 because of its suppression of Ves v 5-specific response. Melittin, a mast cell degranulating peptide from bee venom, was inactive as an adjuvant for Ves v 5-specific response. Conclusion: Yellow jacket venom contains two inflammatory components, mastoparan and phospholipase A1. Our findings suggest that mastoparan can function as a weak adjuvant for TH2 cell-associated antibody response.

© 2003 S. Karger AG, Basel


  

Author Contacts

Correspondence to: Dr. Te Piao King
The Rockefeller University
1230 York Avenue
New York, NY 10021 (USA)
Tel. +1 212 327 8212, Fax +1 212 327 8878, E-Mail kingtp@mail.rockefeller.edu

  

Article Information

Received: September 17, 2002
Accepted after revision: December 19, 2002
Number of Print Pages : 8
Number of Figures : 3, Number of Tables : 2, Number of References : 36

  

Publication Details

International Archives of Allergy and Immunology
Founded 1950
Official Journal of the Collegium Internationale Allergologicum

Vol. 131, No. 1, Year 2003 (Cover Date: May 2003)

Journal Editor: R. Valenta, Vienna
ISSN: 1018–2438 (print), 1423–0097 (Online)

For additional information:http://www.karger.com/iaa


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 9/17/2002
Accepted: 12/19/2002
Published online: 5/16/2003
Issue release date: May 2003

Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 2

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: http://www.karger.com/IAA


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.